Compare OSW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | AGIO |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2019 | 2013 |
| Metric | OSW | AGIO |
|---|---|---|
| Price | $24.20 | $28.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $27.00 | ★ $38.88 |
| AVG Volume (30 Days) | 707.2K | ★ 856.8K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $961,001,000.00 | $43,011,000.00 |
| Revenue This Year | $7.49 | $76.75 |
| Revenue Next Year | $8.52 | $170.73 |
| P/E Ratio | $114.24 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $18.19 | $22.24 |
| 52 Week High | $25.75 | $46.00 |
| Indicator | OSW | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 48.36 |
| Support Level | $23.12 | $26.42 |
| Resistance Level | $25.50 | $29.37 |
| Average True Range (ATR) | 0.76 | 0.95 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 46.94 | 63.67 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.